HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6633-6642

  Murata, Takuya ^a,c   Mizushima, Hiroto ^b   Chinen, Ichino ^b   Moribe, Hiroki ^b   Yagi, Shigeo ^d   Hoffman, Robert M ^e,f   Kimura, Tadashi ^c   Yoshino, Kiyoshi ^c   Ueda, Yutaka ^c   Enomoto, Takayuki ^c   Mekada, Eisuke ^b  

^a SAISEIKAI NAKATSU HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d AntiCancer Japan Incorporated   (Japan)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f ANTICANCER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELL TRANSPLANTATION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; CARCINOMA, SQUAMOUS CELL; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; HELA CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM PROTEINS; PARACRINE COMMUNICATION; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; STROMAL CELLS; TUMOR CELLS, CULTURED; TYRPHOSTINS; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80155192769     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0034     Document Type: Article

References (41)

1. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49. (Pubitemid 39472951)
2. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7. (Pubitemid 39551661)
3. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6:392-401.
4. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48. (Pubitemid 40692295)
5. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008;5:e19.
6. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality, and prevalence worldwide, version 2.0. Lyon, France: IARC; 2004.
7. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
8. Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, et al. Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res 2007;67:7113-23. (Pubitemid 47206538)
9. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-9. (Pubitemid 21926188)
10. Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, Ishikawa M, et al. Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 1995;6:967-80.
11. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 1993;122:933-40. (Pubitemid 23241102)
12. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997;1333:F179-99. (Pubitemid 28015313)
13. Mizushima H, Wang X, Miyamoto S, Mekada E. Integrin signal masks growth-promotion activity of HB-EGF in monolayer cell cultures. J Cell Sci 2009;122:4277-86.
14. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004;64:5720-7. (Pubitemid 39095570)
15. Ito Y, Higashiyama S, Takeda T, Yamamoto Y, Wakasa KI, Matsuura N. Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma. Int J Pancreatol 2001;29:47-52.
16. Inui Y, Higashiyama S, Kawata S, Tamura S, Miyagawa J, Taniguchi N, et al. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 1994;107:1799-804. (Pubitemid 24357636)
17. Ito Y, Takeda T, Higashiyama S, Sakon M, Wakasa KI, Tsujimoto M, et al. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 2001;8:903-7.
18. Naef M, Yokoyama M, Friess H, Buchler MW, Korc M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996;66:315-21. (Pubitemid 26166192)
19. Ito Y, Higashiyama S, Takeda T, Okada M, Matsuura N. Bimodal expression of heparin-binding EGF-like growth factor in colonic neoplasms. Anticancer Res 2001;21:1391-4. (Pubitemid 32494154)
20. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001;61:6227-33. (Pubitemid 32762561)
21. Ito Y, Takeda T, Higashiyama S, Noguchi S, Matsuura N. Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat 2001;67:81-5. (Pubitemid 32703391)
22. Wang YD, De Vos J, Jourdan M, Couderc G, Lu ZY, Rossi JF, et al. Cooperation between heparin-binding EGF-like growth factor andinterleukin-6 in promoting the growth of human myeloma cells. Oncogene 2002;21:2584-92. (Pubitemid 34438111)
23. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005;11:4783-92. (Pubitemid 41557199)
24. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 2006;97:341-7.
25. Gao K, Dai DL, Martinka M, Li G. Prognostic significance of nuclear factor-{kappa}B p105/p50 in human melanoma and its role in cell migration. Cancer Res 2006;66:8382-8. (Pubitemid 44449148)
26. Wang X, Mizushima H, Adachi S, Ohishi M, Iwamoto R, Mekada E. Cytoplasmic domain phosphorylation of heparin-binding EGF-like growth factor. Cell Struct Funct 2006;31:15-27.
27. Hamaoka M, Chinen I, Murata T, Takashima S, Iwamoto R, Mekada E. Anti-human HB-EGF monoclonal antibodies inhibiting ectodomain shedding of HB-EGF and diphtheria toxin binding. J Biochem 2010;148:55-69.
28. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 1995;270:1015-9.
29. Mori S, Heldin CH, Claesson-Welsh L. Ligand-induced polyubiquitination of the platelet-derived growth factor β-receptor. J Biol Chem 1992;267:6429-34.
30. Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 2002;87:84-9. (Pubitemid 36027106)
31. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-15.
32. Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo) radiation and survival in cervical cancer. Clin Cancer Res 2009;15: 7389-97.
33. Kageyama T, Ohishi M, Miyamoto S, Mizushima H, Iwamoto R, Mekada E. Diphtheria toxin mutant CRM197 possesses weak EF2- ADP-ribosyl activity that potentiates its anti-tumorigenic activity. J Biochem 2007;142:95-104. (Pubitemid 351455373)
34. Ichise T, Adachi S, Ohishi M, Ikawa M, Okabe M, Iwamoto R, et al. Humanized gene replacement in mice reveals the contribution of cancer stroma-derived HB-EGF to tumor growth. Cell Struct Funct 2010;35:3-13.
35. Nolan-Stevaux O, Truitt MC, Pahler JC, Olson P, Guinto C, Lee DC, et al. Differential Contribution to Neuroendocrine Tumorigenesis of Parallel Egfr Signaling in Cancer Cells and Pericytes. Genes Cancer 2010;1:125-41.
36. Mine N, Iwamoto R, Mekada E. HB-EGF promotes epithelial cell migration in eyelid development. Development 2005;132:4317-26. (Pubitemid 41576693)
37. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206:1-8. (Pubitemid 41740711)
38. Zhai Y, Hotary KB, Nan B, Bosch FX, Munoz N, Weiss SJ, et al. Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res 2005;65:6543-50. (Pubitemid 41060689)
39. Koshikawa N, Mizushima H, Minegishi T, Iwamoto R, Mekada E, Seiki M. Membrane type 1-matrix metalloproteinase cleaves off the NH2- terminal portion of heparin-binding epidermal growth factor and converts it into a heparin-independent growth factor. Cancer Res 2010;70:6093-103.
40. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
41. Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P. A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res 2009;15:5191-8.